

Available analyses

	Initial test	Follow-up test
Equipment	Kit: - 2x Streck Cell-Free DNA tubes (10 mL) - 1x EDTA blood tube (6 mL) + Tissue kit: Fixed tumour tissue block (FFPE) – prepared by Unilabs	Kit: -2x Streck Cell-Free DNA tubes (10 mL) - No EDTA tube
Goal	Identifies 16 customised molecular markers that identify the patient's tumour DNA	Checks for the presence and quantity of these markers
Turnaround time (TAT)	6 weeks from receipt of the blood and tissue samples at the Natera laboratory (USA), provided no additional material is required.	2 weeks from receipt at the Natera laboratory (USA).
Note	It may take several weeks for our administration team to obtain the biopsy sample, depending on the information and details provided in the initial request. To minimise turnaround times, the referring doctor may contact the pathologists at the laboratory holding the biopsy sample prior to the blood test.	You can request a follow-up test three months after your last Signatera test (whether initial or follow-up).

Kit orders

Unilabs Genetics	Dispatch time
E-mail: secretariat.genetics@unilabs.com Tel: +41 21 321 40 51 Monday – Friday: 8h30 – 16h	1–2 working days

Please try to arrange blood samples at the start of the week and **avoid doing so on Fridays or the day before public holidays** – the samples are sent to Natera (USA) within a maximum of five days of the blood sample being taken.

Billing

These tests are eligible for reimbursement via TARDOC points.

Unilabs will handle the request for insurance coverage with the patient's health insurance provider, provided the patient is insured in Switzerland. For any questions or disputes regarding reimbursement, please contact the following email address::

E-mail: secretariat.cypa@unilabs.com

CC: secretariat.genetics@unilabs.com

Logistics and Operations

If you have any questions regarding the testing process, the Signatera kits and/or logistics, please contact:

E-mail: beryl.royer-bertrand@unilabs.com

Tel: +41 79 502 76 46

CC: secretariat.genetics@unilabs.com

Tel: +41 21 321 40 51

Indications for the Signatera test

Based on the list covered by Medicare in the USA. If you have any questions, please contact:

E-mail: enora.letallec@unilabs.com (MSL)

CC: secretariat.genetics@unilabs.com

Anatomical system	Type of cancer	Details
Digestive system	Colorectal cancer	Stages II to IV, as adjuvant therapy and as part of recurrence monitoring
	Rectal/anal cancer	
	GIST	
	Liver tumours	<i>To be discussed on a case-by-case basis</i>
	Gastric tumours	<i>To be discussed on a case-by-case basis</i>
	Oesophageal tumours	<i>To be discussed on a case-by-case basis</i>
	Pancreatic tumours	<i>To be discussed on a case-by-case basis</i>
	Neuroendocrine tumours	<i>To be discussed on a case-by-case basis</i>
Thoracic apparatus	Non-small cell lung cancer (NSCLC)	Stages I to III under observation.
Urological device	Muscle-invasive bladder cancer (MIBC)	Adjuvant treatment and monitoring for recurrence
	Prostate cancer	<i>To be discussed on a case-by-case basis</i>
Gynaecology	Cancer of the ovary, fallopian tubes and primary peritoneal cancer	Stages II to IV: adjuvant treatment and follow-up
Breast	Breast cancer	Stages II to IV in neoadjuvant treatment, and stages IIb to IV in adjuvant treatment and as part of recurrence monitoring
Hematology	Lymphoma (DLBCL)	Patients with PET-positive end-of-treatment (EOT) DLBCL (the NCCN guidelines recommend this approach as an alternative to biopsy).
Across the board (all cancers)	Monitoring of cancer immunotherapy	Any patient with a solid tumour who is being treated with immune checkpoint inhibitors

For requests for case-by-case analyses (not covered by Medicare), please specify the histological type and tumour grade. The histopathology report may also be attached to the request.

We work closely with Natera's scientific teams to recommend the most appropriate strategy for your patient, drawing on published studies, studies currently being published, and internal case reports.